Ibere Pharmaceuticals announced the pricing of its upsized $120 million IPO this morning and its units are expected to begin trading on the NYSE under the symbol “IBER.U,” today, February 26.
The new company aims to combine with an internationally known pharmaceutical brand that can serve as platform for acquiring drugs with expiring patents. Ibere is led by Chairman and CEO Osagie Imasogie, CFO and EVP Lisa Gray and COO and EVP Zoltan Kerekes.
Total SPAC deal count for 2021 year-to-date is now 188. This offering is expected to close on Tuesday, March 2.
Raymond James & Associates, Inc. is acting as the sole book-running manager for the offering. Shearman & Sterling LLP is serving as Issuer’s Counsel with Ellenoff Grossman & Schole LLP serving as Underwriter’s Counsel. Marcum LLP serves as auditor. Continental Stock Transfer & Trust Company is acting as trustee.
Source: https://spacinsider.com/2021/02/26/ibere-pharmaceuticals-prices-upsized-120m-ipo/
